Disc Medicine says DISC-0974 shows durable anemia responses in RALLY-MF Phase 2 myelofibrosis trial data update at ASCO 2026
Disc Medicine, Inc.
Disc Medicine, Inc. IRON | 0.00 |
- Disc Medicine presented updated Phase 2 RALLY-MF data for DISC-0974 in myelofibrosis-related anemia at the 2026 ASCO meeting.
- Treatment produced durable improvements in anemia across patient subgroups, including those needing transfusions at baseline.
- Responses were consistent in patients on JAK inhibitors, supporting use alongside standard myelofibrosis therapy.
- The safety profile looked manageable, with limited treatment-related side effects reported.
- Additional RALLY-MF data are scheduled for Q4 2026, ahead of an expected end-of-Phase 2 FDA meeting by year-end.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020800PRIMZONEFULLFEED9729740) on June 02, 2026, and is solely responsible for the information contained therein.